Quantcast

Intradermal ID-LV305 Clinical Trial


#1

Another vaccine to target NY-ESO-1 positive tumors but apparently this time there is no restrictions on HLA type:

http://www.clinicaltrials.gov/ct2/show/NCT02122861?term=NCT02122861

HLA stands for Human Leucocyte Antigen and are molecules on the surface of cells that communicate with your immune system. HLA type is determined by a blood test and there are many more different types of HLA than blood types. Unfortunately, the earlier immunotherapy trials targeting NY-ESO-1 were only recruiting patients with type HLA-A2. A lot of people couldn't join these trials because they had the wrong HLA type :-(